Elamipretide Clinical Trials: The Global Research Record

elamipretide's clinical development spans more than a decade and four therapeutic areas, an unusually broad program for a four-residue peptide. The pivotal success came in TAZPOWER (Barth syndrome), which supported the September 2025 accelerated approval of forzinity. Three other completed programs — MMPOWER-3 (primary mitochondrial myopathy), PROGRESS-HF (heart failure) and ReCLAIM (dry age-related macular degeneration) — did not meet their primary endpoints. This pillar is the map of all of it, and each program has a dedicated page in the cluster below.

This page exists because the trial record is the load-bearing evidence structure of the entire topic: the approval, the label parameters summarized in the forzinity pillar, and the safety data pages all trace back to specific trials. When a secondary source claims something about elamipretide, the first question is always which trial, which endpoint, which population — and this page is designed to answer it.

TAZPOWER is the multi-part trial program in Barth syndrome — the X-linked cardiolipin-remodeling disease caused by TAZ variants — that formed the evidence base for the accelerated approval. Its parts examined placebo-controlled and extension observations, including a 168-week extension. Published data demonstrates improvements in secondary measures of muscle strength and function in the labeled population, while primary-endpoint results across trial parts were mixed — the nuance behind the FDA's accelerated (rather than full) approval pathway and its confirmatory obligations. The full design, population and endpoint detail is on the Barth syndrome research page.

The mechanistic logic is unusually direct — a cardiolipin-binding peptide in a cardiolipin-deficiency disease — and the FDA's acceleration decision explicitly balances that logic against the mixed primary-endpoint record. Both halves are documented with sources; neither is editorialized. The brand-level regulatory summary lives on the forzinity fda page.

MMPOWER-3 investigated elamipretide in primary mitochondrial myopathy, the indication closest to the molecule's original academic home territory. The program completed without meeting its primary endpoint, and the sponsor deprioritized the area in subsequent public pipeline disclosures. We document the endpoint definitions and population characteristics because mitochondrial-myopathy research interest in ss-31 remains active in the academic literature.

For researchers, MMPOWER-3 and TAZPOWER together form a natural experiment: related mitochondrial diseases, same molecule, different outcome fidelity. The comparison — population homogeneity, endpoint choice, effect-size visibility — is worked through on the Barth syndrome page and connects to the mechanism discussion on the mechanism research page.

PROGRESS-HF studied daily subcutaneous elamipretide in heart failure with reduced ejection fraction, the largest-population program the molecule has entered. It did not meet its primary endpoint. The result is documented in full — design, dosing schedule as published, population, endpoint — on our forzinity heart failure research page, because “forzinity heart failure” and “elamipretide heart failure” are both heavily searched and dominated by inaccurate secondary summaries.

The heart-failure story is also the clearest example of why evidence tiering matters: preclinical bioenergetics data in cardiac models was strong, human endpoints were not met, and the gap between those two tiers is where most internet content about this molecule goes wrong. Our editorial policy exists for exactly that reason.

ReCLAIM investigated elamipretide for dry age-related macular degeneration, an ophthalmology extension of the mitochondrial-aging hypothesis. The program completed without meeting its co-primary endpoints. The design — including the endpoint measures used for retinal function — and the published readout are summarized with sources on our AMD research page.

AMD matters to this cluster because “forzinity amd” searches conflate two very different things: an investigational program that missed its endpoints, and the separate approved Barth-syndrome label. The research directions themselves remain legitimate academic territory — summarized on the elamipretide uses page with evidence tiers attached to each.

The 168-week TAZPOWER extension is the longest published exposure window in the record, and it carries particular weight for the safety literature: eosinophilia observations (documented on our eosinophilia page) and injection-site reaction rates (on the reactions page) both draw on extended-exposure populations. Where an endpoint figure and an extension figure exist for the same measure, we cite both with their observation windows.

Long-term extension data comes with a known caveat set — open-label phases, attrition, small-n drift — which we state on each page rather than smoothing over. The same discipline applies to the cross-trial safety aggregation on the elamipretide side effects page.

Trial numbers answer different questions depending on design, and the three-step discipline from the forzinity pillar extends naturally here. First, identify the endpoint hierarchy: a primary endpoint miss with secondary-measure improvements (the TAZPOWER pattern) is a different result from a uniform null (the PROGRESS-HF pattern), and both differ from a safety-driven discontinuation — none of which happened in this record. Second, check the population: Barth syndrome trialists are genetically stratified; heart-failure populations are broad; effect-size visibility differs accordingly.

Third, date everything: the trial record is now intersected by a regulatory record (approval, label revisions, confirmatory obligations) that keeps moving. Where our pages cite label frequencies — erythema 100%, pain 75%, pruritus 67% — those are label-document figures for the approved population, not cross-trial averages. The safety overview keeps the two apart.

Across the program, elamipretide was studied as daily subcutaneous administration, and the approved label consolidated this into the 40 mg daily regimen documented on the forzinity dosage data page — with renal-impairment figures (20 mg daily) and pharmacokinetic parameters (half-life approximately 4 hours) from the same documentation. We present dosing exclusively as published data description: trial designs and label parameters, never instructions.

That framing is not a legal nicety; it is the epistemically correct one. Trial dosing is a controlled variable in experiments, not a recommendation; any individual-context question belongs to clinicians with access to the label and the patient. Our data-usage steps below apply this discipline to every number on every page in this cluster.

The trial-comparison table at the bottom of this page is the cluster's normalization layer: every program reduced to the same fields — phase, population, regimen as published, primary endpoint, result, and the page where the detail lives. To use it: identify the trial your question is actually about; open its dedicated page; extract the endpoint definitions before extracting the numbers; and only then compare across trials.

For citations, prefer the primary publication and the regulatory document over this or any summary; our editorial policy defines the tiers. Where this site and a primary source ever conflict, the primary source wins — and we want to know, because correction is part of the editorial process.

Per-area pages: Barth syndrome, heart failure, AMD, plus forzinity clinical trial data (the brand-side TAZPOWER summary). Upstream: the elamipretide molecule pillar for mechanism and structure; the forzinity pillar for label, regulatory and market context. Safety data pages hang off the safety overview; market and access research off the cost pillar.

Every page in this cluster links back here and to at least one sibling — the closed-loop topology that keeps trial data, safety data and market data from fragmenting into isolated pages that compete with each other.